Literature DB >> 22301094

HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes.

Julieta Díaz-Delfín1, Pere Domingo, Martin Wabitsch, Marta Giralt, Francesc Villarroya.   

Abstract

BACKGROUND: HIV-1 Tat protein has been shown to play multiple roles in the pathogenesis of AIDS; however, there is no information currently available on its effects on adipose tissue alterations. We have studied the effects of Tat on SGBS adipocytes to gain insight on its role on the development of lipodystrophy.
METHODS: SGBS preadipocytes were exposed to Tat during and after differentiation. Acquisition of adipocyte morphology, expression of gene markers of adipogenesis and inflammation, release of adipokines and cytokines to the medium, and glucose uptake were measured. The action of Tat on tumour necrosis factor (TNF)-α-regulated messenger RNA expression was determined in differentiated adipocytes. The capacity of rosiglitazone, resveratrol and parthenolide to influence the action of Tat was also assessed.
RESULTS: Tat treatment reduced the number of SGBS preadipocytes that acquired adipocyte morphology. It also led to repression of adipogenic gene expression and induced the coordinate expression and release of proinflammatory cytokines in human adipose cells. Moreover, combined treatment with Tat and TNF-α produced an additive effect on the repression of adipocyte genes. The observed effects of Tat on gene transcription in adipocytes were due, in part, to TNF-α that was secreted as a consequence of intracellular exposure to Tat.
CONCLUSIONS: Tat impairs adipogenesis in human SGBS preadipocytes and increases the expression and release of proinflammatory cytokines. Positive crosstalk between Tat and TNF-α contributes to the anti-adipogenic and proinflammatory effects. HIV-1 Tat protein may play a role in the adipose tissue alterations that ultimately lead to lipoatrophy and systemic metabolic disturbances observed in HIV-1-infected patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22301094     DOI: 10.3851/IMP2021

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  16 in total

Review 1.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

2.  Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications.

Authors:  Catherine Godfrey; Andrew Bremer; Diana Alba; Caroline Apovian; John R Koethe; Suneil Koliwad; Dorothy Lewis; Janet Lo; Grace A McComsey; Allison Eckard; Suman Srinivasa; Janine Trevillyan; Clovis Palmer; Steven Grinspoon
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

Review 3.  HIV Persistence in Adipose Tissue Reservoirs.

Authors:  Jacob Couturier; Dorothy E Lewis
Journal:  Curr HIV/AIDS Rep       Date:  2018-02       Impact factor: 5.071

Review 4.  Adipose Tissue in HIV Infection.

Authors:  John R Koethe
Journal:  Compr Physiol       Date:  2017-09-12       Impact factor: 9.090

5.  Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus.

Authors:  Paula Debroy; Jordan E Lake; Carlee Moser; Maxine Olefsky; Kristine M Erlandson; Ann Scherzinger; James H Stein; Judith S Currier; Todd T Brown; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2021-03-15       Impact factor: 9.079

Review 6.  The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection.

Authors:  Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2017-12       Impact factor: 5.071

Review 7.  Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?

Authors:  Jennifer Totonchy; Ethel Cesarman
Journal:  Curr Opin Virol       Date:  2016-09-23       Impact factor: 7.090

8.  Adipose Tissue Is a Neglected Viral Reservoir and an Inflammatory Site during Chronic HIV and SIV Infection.

Authors:  Abderaouf Damouche; Thierry Lazure; Véronique Avettand-Fènoël; Nicolas Huot; Nathalie Dejucq-Rainsford; Anne-Pascale Satie; Adeline Mélard; Ludivine David; Céline Gommet; Jade Ghosn; Nicolas Noel; Guillaume Pourcher; Valérie Martinez; Stéphane Benoist; Véronique Béréziat; Antonio Cosma; Benoit Favier; Bruno Vaslin; Christine Rouzioux; Jacqueline Capeau; Michaela Müller-Trutwin; Nathalie Dereuddre-Bosquet; Roger Le Grand; Olivier Lambotte; Christine Bourgeois
Journal:  PLoS Pathog       Date:  2015-09-24       Impact factor: 6.823

9.  Switch to Efavirenz Attenuates Lipoatrophy in Girls With Perinatal HIV.

Authors:  Junwei Su; Stephanie Shiau; Stephen M Arpadi; Renate Strehlau; Megan Burke; Faeezah Patel; Louise Kuhn; Ashraf Coovadia; Michael T Yin
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-01-01       Impact factor: 2.839

10.  Infectious SIV resides in adipose tissue and induces metabolic defects in chronically infected rhesus macaques.

Authors:  Jacob Couturier; Neeti Agarwal; Pramod N Nehete; Wallace B Baze; Michael A Barry; K Jagannadha Sastry; Ashok Balasubramanyam; Dorothy E Lewis
Journal:  Retrovirology       Date:  2016-04-27       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.